Showing 4171-4180 of 5000 results for "".
- Otezla Becomes First Oral Psoriasis Treatment Approved Across All Disease Severitieshttps://practicaldermatology.com/news/otezla-becomes-first-oral-psoriasis-treatment-approved-across-all-disease-severities/2461014/Otezla® (apremilast) from Amgen is now approved for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. This expanded indication makes Otezla the first and only oral treatment approved 
- Top Researcher of Itch and Inflammatory Skin Conditions to Join Mount Sinai’s Department of Dermatologyhttps://practicaldermatology.com/news/top-researcher-of-itch-and-inflammatory-skin-conditions-to-join-mount-sinais-department-of-dermatology/2461006/One of the top researchers worldwide studying itch and inflammatory skin conditions, Brian S. Kim, MD, MTR, FAAD, will join Mount Sinai Health System as Director of the newly established Mark Lebwohl Center for Neuroinflammation and Sensation. Dr. Kim will also be Vice Chair of Research of the Ki
- Novel Lyme Vaccine Shows Promise in Early Researchhttps://practicaldermatology.com/news/novel-lyme-vaccine-shows-promise-in-early-research/2460994/Yale University researchers have developed a novel vaccine that in guinea pigs offers protection against infection by the bacterium that causes Lyme disease and may also combat other tick-borne diseases, they report in the journal Science Translational Medicine. Instead of trig
- Abreva Launches #StopBullyingYourself Campaign for People with Cold Soreshttps://practicaldermatology.com/news/abreva-launches-stopbullyingyourself-campaign-for-people-with-cold-sores/2460993/People with cold sores tend to beat themselves up, according to a new survey from Abreva. As many as 80 percent of people with cold sores feel misunderstood and want others to know it is a common affliction and that cold sores do not mean that they are
- Derms Give Back: Caring for Veteranshttps://practicaldermatology.com/news/derms-give-back-caring-for-veterans/2460989/Caring for veterans inspires dermatologists like Joshua E. Lane, MD every single day. Dr. Lane practices in Columbus, GA, near Fort Benning, a large military base, and many of his patients are veterans. He was so moved by their service and selflessness that he joined the
- With New Agreement, DermTech Melanoma Test Available Through DermatologistOnCallhttps://practicaldermatology.com/news/with-new-agreement-dermtech-melanoma-test-available-through-dermatologistoncall/2460987/The DermTech Melanoma Test is now available through DermatologistOnCall’s telemedicine platform. The DermTech Melanoma Test is a non-invasive test used to painlessly collect cellular material from the surface of a patient’s mole via t
- PsA Treatment Snapshot: Study Highlights Trends in PsA Treatment Since 2018https://practicaldermatology.com/news/psa-treatment-snapshot-study-highlights-trends-in-psa-treatment-since-2018/2460985/There’s been a significant increase in anti-IL17 and anti-phosphodiesterase-4 (anti-PDE4) medications being used as initial treatment for psoriatic arthritis (PsA) since 2018, which may reflect their inclusion as potential initial therapy in the American College of Rheumatology/National Pso
- Gryphon Investors to Acquire Revision Skincarehttps://practicaldermatology.com/news/gryphon-investors-to-acquire-revision-skincare/2460984/Gryphon Investors is set to acquire Revision Skincare and Goodier Cosmetics. The middle-market private equity firm has signed a definitive agreement to acquire the skincare company, with an anticipating closing date this year. Financial terms of the transaction were not disclosed.
- European Medicines Agency Set to Review Incyte’s Ruxolitinib Cream in Vitiligohttps://practicaldermatology.com/news/european-medicines-agency-set-to-review-incytes-ruxolitinib-cream-in-vitiligo/2460970/The European Medicines Agency validated the European Marketing Authorization for Incyte’s ruxolitinib cream as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement. The validation of the Marketing Author
- Potential Melanoma Treatment Breakthrough: Is KDM5B the Key?https://practicaldermatology.com/news/potential-melanoma-treatment-breakthrough-is-kdm5b-the-key/2460964/The enzyme KDM5B may suppress anti-melanoma immunity, and these findings could help lead to the development of a new treatment strategy to benefit patients with melanoma and other cancers, according to a new study out of the Yale Cancer Center in New Haven, Conn. The research